Item type: | Article | ||||
---|---|---|---|---|---|
Journal or Publication Title: | Transplantation and Cellular Therapy | ||||
Publisher: | Elsevier | ||||
Place of Publication: | NEW YORK | ||||
Volume: | 28 | ||||
Number of Issue or Book Chapter: | 6 | ||||
Page Range: | 335.e1-335.e17 | ||||
Date: | 2022 | ||||
Institutions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
Identification Number: |
| ||||
Keywords: | LONG-TERM SURVIVORS; VERSUS-HOST-DISEASE; BONE-MINERAL DENSITY; 2ND SOLID CANCERS; NEW-SOUTH-WALES; AMERICAN SOCIETY; LICHEN-SCLEROSUS; SEXUAL FUNCTION; TESTOSTERONE REPLACEMENT; FERTILITY PRESERVATION; Survivorship; Late effects; Male-specific; Hematopoietic cell transplantation; Genital Chronic graft-versus-host disease; Hypogonadism; Sexual dysfunction; Infertility; Subsequent malignancies | ||||
Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
Status: | Published | ||||
Refereed: | Yes, this version has been refereed | ||||
Created at the University of Regensburg: | Yes | ||||
Item ID: | 57826 |
Abstract
Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host dis-ease (GVHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies, such as prostate, penile, and testicular cancer. These effects may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. Here we provide a systematic ...
Abstract
Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host dis-ease (GVHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies, such as prostate, penile, and testicular cancer. These effects may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. Here we provide a systematic review of male-specific late effects in a collaboration among transplantation physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. We used a sys-tematic review methodology to summarize incidence, risk factors, screening, prevention, and treatment of these com-plications and provide consensus evidence-based recommendations for clinical practice and future research. Most of the evidence regarding male GVHD is still based on limited data, precluding strong therapeutic recommendations. Therefore, we recommend systematic screening for male genital GVHD regularly and reporting of cases to large regis-tries to allow for a better understanding. Future research also should address treatment, given the little published evi-dence currently available. Male-specific endocrine consequences of HCT include hypogonadism, which also may affect bone health. Given the scanty evidence, current recommendations for hormone substitution and/or bone health treat-ment are based on similar principles as for the general population. Following HCT, sexual health decreases, and this topic should be addressed at regular intervals. Future studies should focus on interventional strategies to address sex-ual dysfunction. Infertility remains prevalent in patients having undergone myeloablative conditioning, warranting the offer of sperm preservation for all HCT candidates. Most studies on fertility rely on descriptive registry analysis and surveys, underscoring the importance of reporting post-HCT conception data to large registries. Although the quality of evidence is low, the development of cancer in male genital organs does not seem more prevalent in HCT recipients compared with the general population; however, subsequent malignancies in general seem to be more prevalent in males than in females, and special attention should be given to skin and oral mucosa. Male-specific late effects, which likely are more underreported than female-specific complications, should be systematically considered during the reg-ular follow-up visits of male survivors who have undergone HCT. Care of patients with male-specific late effects war-rants close collaboration between transplantation physicians and specialists from other involved disciplines. Future research should be directed toward better data collection on male-specific late effects and on studies about the interre-lationships among these late effects, to allow the development of evidence-based effective management practices. (c) 2022 The American Society for Transplantation and Cellular Therapy and Springer Nature. Published by Elsevier Inc. All rights reserved.
Metadata last modified: 29 Feb 2024 13:02